The Carolina Breast Cancer Study (CBCS) Phase III is a continuation of a successful SPORE-supported population-based study examining genetic and epidemiologic risk factors and characteristics of breast cancer with a focus on African-American (AA) and premenopausal breast cancer. Studies from the approximately 2000 breast cancer patients participating in CBCS Phases I and II demonstrated that patients with AA race and young age had a high prevalence ofthe poor prognosis Basal-like breast cancer, and conversely a low prevalence ofthe good prognosis Luminal A subtype. Additionally, reevaluafion of traditional risk factors suggested considerable heterogeneity in effects by subtype;unique genetic and lifestyle factor associations have been observed for basal-like breast cancer, sometimes with effects in the opposite direction as expected based on associations with overall breast cancer risk. Based on these results, we hypothesize that the higher incidence and mortality from breast cancer in younger African American women compared to white women is due to a combination of factors, including differences in tumor biology, access to care, and type of treatment received. Furthermore, we hypothesize that continued comprehensive investigation of these factors will identify specific clinical and public health interventions to lower breast cancer mortality. To identify the factors that are associated with each breast cancer subtype, CBCS Phase III was opened in 2008, expanding the previous 24-county catchment area of Phases l-ll to 44 counties across North Carolina, and will accrue an additional 1500 AA women and 1500 non-AA women by 2014. The goal of CBCS III is to identify determinants of disparities in breast cancer clinical outcomes, including biologic, racial, socioeconomic, behavioral factors, and to identify modifiable factors in clinical care (delivery and access) that address the causes of disparities. CBCS Phase III is beyond the scope of a single funding source and is broadly supported by the University and other mechanisms, however there are crucial translational implications of this project. Specifically, SPORE funding for gene expression profiling on the tumors (Aim 1), which will enable evaluation of differences in risk factors distribution by subtype (Aim 2), and will be used for collection of treatment and outcome data to assess survival outcomes (Aim 3). This study will provide a comprehensive picture ofthe biology and epidemiology of breast cancer and breast cancer disparities, from risk to survival.

Public Health Relevance

Examination of factors affecting risk, behavior, and prognosis within and across tumor subtypes, and between AA and non-AA women, will identify determinants of racial disparities in breast cancer risk and outcome.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA058223-20
Application #
8547136
Study Section
Special Emphasis Panel (ZCA1-RPRB-0)
Project Start
Project End
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
20
Fiscal Year
2013
Total Cost
$768,483
Indirect Cost
$616,646
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Cai, Ling; Tsai, Yi-Hsuan; Wang, Ping et al. (2018) ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer. Mol Cell 72:341-354.e6
Bensen, Jeannette T; Graff, Mariaelisa; Young, Kristin L et al. (2018) A survey of microRNA single nucleotide polymorphisms identifies novel breast cancer susceptibility loci in a case-control, population-based study of African-American women. Breast Cancer Res 20:45
Puvanesarajah, Samantha; Nyante, Sarah J; Kuzmiak, Cherie M et al. (2018) PAM50 and Risk of Recurrence Scores for Interval Breast Cancers. Cancer Prev Res (Phila) 11:327-336
Knott, Simon R V; Wagenblast, Elvin; Khan, Showkhin et al. (2018) Asparagine bioavailability governs metastasis in a model of breast cancer. Nature 554:378-381
McRee, Autumn J; Marcom, Paul K; Moore, Dominic T et al. (2018) A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast Cancer. Clin Breast Cancer 18:289-297
DeBono, Nathan L; Robinson, Whitney R; Lund, Jennifer L et al. (2018) Race, Menopausal Hormone Therapy, and Invasive Breast Cancer in the Carolina Breast Cancer Study. J Womens Health (Larchmt) 27:377-386
Nasarre, Patrick; Bonilla, Ingrid V; Metcalf, John S et al. (2018) TRAF3-interacting protein 3, a new oncotarget, promotes tumor growth in melanoma. Melanoma Res 28:185-194
Pearce, Oliver M T; Delaine-Smith, Robin M; Maniati, Eleni et al. (2018) Deconstruction of a Metastatic Tumor Microenvironment Reveals a Common Matrix Response in Human Cancers. Cancer Discov 8:304-319
Williams, Lindsay A; Nichols, Hazel B; Hoadley, Katherine A et al. (2018) Reproductive risk factor associations with lobular and ductal carcinoma in the Carolina Breast Cancer Study. Cancer Causes Control 29:25-32
Couture, Heather D; Williams, Lindsay A; Geradts, Joseph et al. (2018) Image analysis with deep learning to predict breast cancer grade, ER status, histologic subtype, and intrinsic subtype. NPJ Breast Cancer 4:30

Showing the most recent 10 out of 598 publications